# Effect of Sorafenib on ccRCC Uptake of Radiolabeled Bevacizumab or cG250

> **NCT00602862** · NA · COMPLETED · sponsor: **Radboud University Medical Center** · enrollment: 26 (actual)

## Conditions studied

- Clear Cell Renal Cell Carcinoma

## Interventions

- **DRUG:** Sorafenib
- **DRUG:** 111Indium-bevacizumab
- **DRUG:** 111Indium-cG250

## Key facts

- **NCT ID:** NCT00602862
- **Lead sponsor:** Radboud University Medical Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07
- **Primary completion:** 2012-04
- **Final completion:** 2012-06
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2013-12-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00602862

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00602862, "Effect of Sorafenib on ccRCC Uptake of Radiolabeled Bevacizumab or cG250". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT00602862. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*